EGFR and non-small cell lung carcinoma: Recently, specifically designed inhibitors against ex20ins including EGFR‐MET bispecific monoclonal antibody amivantamab (JNJ‐61186372) and novel inhibitor mobocertinib (TAK‐788) showed high selectivity and potency, and have been approved by the Food and Drug Administration (FDA) of U.S.A. for the treatment of metastatic NSCLC patients with EGFR ex20ins failed to prior platinum‐based chemotherapy.13, 14